
Bryan Kee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/264509/publications.pdf Version: 2024-02-01



ROVAN KEE

#	Article	IF	CITATIONS
1	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
2	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	1.0	108
3	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
4	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> ^{G12C} -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	1.5	31
5	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	3.2	28
6	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	1.1	25
7	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 137-147.e1.	1.0	17
8	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget, 2014, 5, 6584-6593.	0.8	14
9	Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstetric Medicine, 0, , 1753495X2110412.	0.5	4
10	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	1.0	3
11	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 48-56.e2.	1.0	2
12	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 647-656.	0.6	2
13	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	1.0	1